Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Unoprostone - R-Tech Ueno Ltd

Next Previous
Drug Profile

Unoprostone - R-Tech Ueno Ltd

Alternative Names: Isopropyl unoprostone; Ocuseva; Rescula; UF-021; Unoprostone isopropyl 0.12%

Latest Information Update: 06 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator R-Tech Ueno Ltd
  • Developer R-Tech Ueno Ltd; Santen Pharmaceutical; Sucampo Pharmaceuticals
  • Class Antiglaucomas; Antihypertensives; Eye disorder therapies; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Nitric oxide stimulants; Potassium channel agonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension
  • Phase III Retinitis pigmentosa
  • Phase I/II Retinal detachment
  • No development reported Age-related macular degeneration

Most Recent Events

  • 28 May 2018 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Japan (Ophthalmic, Drops)
  • 13 Feb 2018 Sucampo Pharmaceuticals has been acquired and merged into Mallinckrodt plc
  • 04 Jan 2017 Launched for Ocular hypertension in Japan (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top